Clinical Characteristics of Patients with Micrococcus luteus Bloodstream Infection in a Chinese Tertiary-Care Hospital by ZHU, MINGHUI et al.
Polish Journal of Microbiology
2021, Vol. 70, No 3, 321–326
https://doi.org/10.33073/pjm-2021-030
ORIGINAL PAPER
# Minghui Zhu and Qiang Zhu contributed equally to this study.
* Corresponding author: Z. Liang, Department of Respiratory Diseases, First Medical Center of Chinese People’s Liberation Army General 
Hospital, Beijing, China e-mail: Liangzhixin301@163.com 
© 2021 Minghui Zhu et al.
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License (https://creativecommons.
org/licenses/by-nc-nd/4.0/).
Introduction
Micrococcus luteus, a member of the Micrococcus 
family, is a kind of catalase-, oxidase-, and Gram-posi-
tive cocci broadly found in natural environments such 
as soil and water resources and it is usually considered 
a normal inhabitant of human skin and oropharynx 
mucosa (Erbasan 2018). In 1922, Alexander Fleming, 
discoverer of penicillin, first found M. luteus in the 
nasal secretion of a patient. In recent years, M. luteus 
has been reported to possibly cause infections such as 
hepatic and brain abscess, native valve endocarditis, 
bacteremia, and septic arthritis in immunosuppres- 
sive patients (Wharton et al. 1986; Peces et al. 1997; 
Andreopoulos et al. 2000; Erbasan 2018; Ianniello et al. 
2019). It indicates that M. luteus should be considered 
as a clinically potential opportunistic pathogen.
However, few studies have focused on M. luteus 
infection, especially in bloodstream infections (BSI), 
because of its low pathogenicity and incidence. A Med-
line search revealed only three case reports on M. luteus 
BSI, indicating that the clinical features of the patients 
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Few pieces of research have focused on Micrococcus luteus blood-
stream infection (BSI) because of its low incidence; hence data 
is needed to illustrate this uncommon infection. This study aimed to 
explore the clinical characteristics of patients with M. luteus BSI. 
From January 2010 to December 2019, inpatients that met the crite-
ria for M. luteus BSI were included in this study. Data was collec ted 
by reviewing electronic records. Ninety-seven patients were enrolled 
in this study. Sixty-three percent of the patients have a  higher 
neutrophil percentage (NEUT%). The average blood C-reactive 
protein (CRP) concentration was 5.5 ± 6.4 mg/dl. 48.5% of the 
patients had malignancy, and 40.2% underwent invasive surgeries. 
Linezolid was found to have the largest average diameter of the 
inhibition zone (36 mm), while erythromycin was found to have the 
smallest average zone diameter (15 mm). However, some M. luteus 
strains had a potentially broad antimicrobial resistance spectrum. 
Cephalosporins (59.2%) and quinolones (21.4%) were the most 
commonly used antibiotics for empirical therapies. In conclusion, 
M. luteus BSI mainly happens in immunocompromised patients 
or those with former invasive surgeries or indwelling catheters. 
M. luteus strains are less responsive to erythromycin. Cephalospor-
ins and quinolones are effective empirical antibiotics for M. luteus 
BSI; however, vancomycin and teicoplanin should be considered for 
potentially broadly drug-resistant M. luteus strains.
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remained uncertain. Hence, we described the clinical 
characteristics of patients with M. luteus BSI in a ter-
tiary-care hospital in China, hoping to provide more 
information for this infrequent infection.
Experimental
Materials and Methods
Setting and design of the study. This retrospective 
study was performed at the First Medical Center of 
Chinese People’s Liberation Army General Hospital 
(FMC-PLAGH) in Beijing, China. FMC-PLAGH is one 
of the largest tertiary-care hospitals in China, with more 
than 2,400 beds and 150 thousand inpatients per year.
From January 2010 to December 2019, inpatients 
with at least two consecutive blood culture results posi-
tive for M. luteus were included in this study. Data of 
the enrolled patients was collected by reviewing the 
electronic records of the Infection Management and 
Disease Control Department of FMC-PLAGH. The 
included information was as followed: age, gender, body 
mass index (BMI), hospitalization department, risk fac-
tors, laboratory examination results, admission time, 
hospitalization time, Sequential Organ Failure Assess-
ment (SOFA) score, type of antibiotics used, results of 
antimicrobial susceptibility test, and outcome. 
Definitions. The diagnosis of M. luteus BSI met 
the following criteria: 1) isolation of at least two con-
secutive blood culture samples positive for M. luteus; 
2) having one of the following symptoms: fever, chill, 
or hypotension; and 3) exclusion of contamination dur-
ing the process of sample collection and blood culture 
(CDC 2021). Incidence of M. luteus BSI was calculated 
as cases divided by the admission number of the year. 
BSI was considered as a community-acquired when the 
positive blood culture was obtained within 48 h after 
admission. In comparison it was considered as hospital-
acquired when it happened beyond 48 h after admis-
sion. Antimicrobial therapies are considered empirical 
when they are used before the susceptibility test results 
are available, and they are considered definitive after 
the results of susceptibility tests return.
Blood culture, identification, and antimicrobial 
susceptibility test. Blood culture, identification, and 
antimicrobial susceptibility test were performed in the 
Microbiology Center of FMC-PLAGH. BacT/ALERT 
3D system (Becton-Dickinson, Sparks, MD, USA) was 
used for blood culture. Species identification was per-
formed using VITEK 2 system (BioMérieux, Marcy 
l’Étoile, France) and confirmed using a MALDI-TOF 
technology via VITEK-MS system (BioMérieux, Marcy 
l’Étoile, France). An antimicrobial susceptibility test 
was performed by either a Kirby-Bauer Disk Diffusion 
method (Oxoid, UK) or the VITEK 2 system. Due to the 
lack of recommended standards for defining the suscep-
tibility of M. luteus to the antimicrobial agents used in 
this study, only diameters of the inhibition zone or mini-
mum inhibitory concentrations (MIC) were reported. 
Results
Epidemiological trends of M. luteus BSI in FMC-
PLAGH. As shown in Fig. 1, during the nine-years, 
the incidence of M. luteus BSI ranged from 0 to 12.6 
per 100,000, and the proportion among all BSIs ranged 
between 0 and 20.3 per 1,000. The overall incidence and 
proportion among all BSIs for M. luteus BSI was 6.7 per 
100,000 and 9.5 per 1,000, respectively. The results indi-
cated that M. luteus was still an uncommon pathogen 
for BSI; however, the odds seemed to be rising from 
2010 to 2018. 
Characteristics of the patients with M. luteus 
BSI. The clinical characteristics of the patients with 
M. luteus BSI were listed in Table I. A total of 97 patients 
with M. luteus BSI were identified during the 2010–
2019  period, among which three died during their 
hospital stay. The average age was 51.9 ± 22.0 years old, 
and 62.9% of the patients were male. The average Body 
Mass Index (BMI) was within the normal range, and 
the SOFA score of the patients was 1.4 ± 1.8. Most of 
the BSIs were acquired in the hospital (72.2%). More-
over, polymicrobial BSI was not commonly seen in 
M. luteus BSIs (5.2%). Nearly 90% of the patients suf-
fered from fever, followed by chill (18.6%) and fatigue 
(12.4%). The average maximal body temperature of 
patients with M. luteus BSI was 38.7 ± 0.9°C (normal 
range 36.3–37.2°C, axillary temperature). As for labora-






















Fig. 1. Epidemiological trends of Micrococcus luteus bloodstream 
infection (BSI) in the First Medical Center of the Chinese People’s 
Liberation Army General Hospital. Incidence was calculated as 
cases divided by the admission number of the year. Data for 2019 
was unavailable due to a lack of hospital admission number.
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had abnormal white blood cell (WBC) count results; 
however, around two-thirds were having a  higher 
neutrophil percentage (NEUT%). The average C-reac-
tive protein (CRP) concentration was 5.5 ± 6.4 mg/dl, 
which was more elevated than the upper limit of the 
normal range (0.8 mg/dl). 48.5% of the patients had 
malignancy, followed by immune diseases (15.5%), 
and infectious diseases (13.4%). In addition, 40.2% of 
Age (year), mean ± SD (range) 51.9 ± 22.0 (2–92)
  Age ≤ 12 8 (8.2)
  Age ≥ 60 38 (39.2)
Male 61 (62.9)
BMI, mean ± SD (range) 22.6 ± 4.5 (13.4–35.4)




Hospitalization time (day), mean ± SD (range) 32.2 ± 36.4 (6–267)





Maximal body temperature (T, °C), mean ± SD (range) 38.7 ± 0.9 (36.5–41.0)
  37.2 < T ≤ 38 8 (8.2)
  38 < T ≤ 39 43 (44.3)
  39 < T ≤ 41 36 (37.1)
WBC count (× 109/l), mean ± SD (range) 7.9 ± 4.3 (0.6–21.8)
WBC count above 10 × 109/l (n = 95) 31 (32.6)
NEUT%, mean ± SD (range) 72.2 ± 18.3 (4–97.6)
NEUT% above 70% (n = 92) 58 (63.0)
CRP concentration (mg/dl), mean ± SD (range) 5.5 ± 6.4 (0.09–33.5)
CRP above 0.8 mg/dl (n = 79) 60 (75.9)
Underlying diseases
Malignancy 47 (48.5)
Immune diseases 15 (15.5)
Infectious diseases 13 (13.4)
Risk factors
Underwent invasive surgery 39 (40.2)
With indwelling catheter 37 (38.1)
ICU stay 15 (15.5)





Lung infection, renal failure 1 (33.3)
Pancreatic cancer, hepatic encephalopathy 1 (33.3)
Acute leukemia 1 (33.3)
Table I
Characteristics of the patients with M. luteus BSI.
BMI – body mass index, SOFA – sequential organ failure assessment,
WBC – white blood cell, NEUT% – neutrophil percentage, CRP – C-reactive protein,
ICU – intensive care unit
Variable Value
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the patients underwent invasive surgeries, while 38.1% 
had an indwelling catheter.
Antimicrobial susceptibility test. As shown in 
Table II and Table SI, data of antimicrobial susceptibil-
ity tests for 90 patients were collected and analyzed. Of 
the 14 antibiotics tested, linezolid was found to have 
the largest diameter of the inhibition zone (36 mm), fol-
lowed by cefoxitin (35 mm), rifampin (33 mm), cefazo-
lin (32 mm), and penicillin (32 mm), while erythromy-
cin was found to have the most minor average diameter 
of the inhibition zone (15 mm). Overall, except for ery-
thromycin, all the other antimicrobial agents tested were 
considered to have a strong effect against M. luteus. 
However, some M. luteus strains were found to be com-
paratively less responsive to gentamycin, cephalospor-
ins, levofloxacin, and carbapenems comparing to other 
strains (Table SI, strains nos. 5, 15, 51, 69, and 92). 
Antimicrobial treatment for patients with M. luteus 
BSI. All the patients with M. luteus BSI received anti-
microbial treatment. 
Cephalosporins (59.2%) and quinolones (21.4%) 
were the most commonly used antibiotics for empiri-
cal therapies. After the results of susceptibility tests 
returned, the antibiotic usage shifted to cephalospor-
ins (35.2%), glycopeptides (26.7%), and carbapenems 
(18.1%). The results were shown in Table SII. 
Discussion
According to the College of American Patholo-
gists, Micrococcus species used to be considered one of 
the most common blood contaminants (Dargère et al. 
2018). However, some subsets, such as M. luteus, have 
been proven to cause infections under certain circum-
stances (Fosse et al. 1985; Hirata et al. 2009; Ianniello 
et al. 2019). At present, it is still challenging to dis-
tinguish between M. luteus infection and contamina-
tion. Clinical judgment, positive blood culture bottles, 
short time to growth period (time of bacterial inocu-
lation to detection), and new microbiologic technolo-
gies are considered possible methods to avoid blood 
culture contamination. In our study, all the patients 
had at least two consecutive positive blood culture 
results. They had BSI-related clinical symptoms, with 
a  comparatively short time to growth period, and in 
most cases (94.8%) M. luteus was the only pathogen 
identified. These showed that the patients were more 
likely to suffer from M. luteus BSI than blood culture 
contamination.
From 2010 to 2019, 97 patients with M. luteus BSI 
were included in this study, making it the study with 
the largest sample size to date. According to our results, 
M. luteus is an uncommon BSI pathogen, with inci-
dence lower than 13 per 100,000. A favorable prognosis 
was expected in patients with M. luteus BSI, as most 
patients had low SOFA scores and survived through 
their hospitalization. Those who died were suffering 
from other severe diseases rather than M. luteus BSI 
(Table  I), indicating that M. luteus was of low viru-
lence. The most common features of patients with 
M. luteus BSI are abrupt fever, high blood NEUT%, 
and CRP concentration, and comparatively normal 
WBC count results. Immunocompromised patients, 
especially those who undergo invasive operations or 
with indwelling catheters, are more likely to suffer from 
M. luteus BSI, according to former research (Miltiadous 
















Results of antimicrobial susceptibility tests
Antimicrobial agent Numberof samples
Average diameter
of inhibition zone (mm)
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As only a few cases of M. luteus BSI was confirmed 
during recent decades, the detailed antibiotic suscepti-
bility of M. luteus remained unclear. Here we presented 
data of different isolates from 90 patients (Table II and 
Table SI). Due to the lack of evidence of proper break-
points for zone diameters and MICs for M. luteus, we 
were unlikely to judge if the isolates were susceptible 
or resistant to a specific antibiotic precisely. Hence, 
we only reported the average diameters of inhibi-
tion zones in this study. Overall, the average inhibi-
tion zone diameters of most of the antibiotics tested 
were large, ranging from 25 mm to 36 mm. Erythro-
mycin, however, was found to have a smaller average 
diameter of inhibition zone (15 mm), which might be 
attributed to the existence of certain linear plasmids. 
In 2002 and 2010, Wolfgang Liebl and Julian R. Dib 
discovered two novel plasmids designated pMEC2 and 
pLMA1, which conferred resistance to erythromycin 
in M. luteus (Liebl et al. 2002; Dib et al. 2010). Hence 
macrolides such as erythromycin are not recommended 
as antimicrobial agents for M. luteus BSIs. Although 
most M. luteus strains were responsive to almost every 
antibiotic tested, some isolates were found to be less 
responsive to gentamycin, most cephalosporins, levo-
floxacin, and even carbapenems (Table SI, No. 5, 15, 
51, 69, and 92). For BSI induced by these M. luteus 
strains, glycopeptides should be considered for anti- 
microbial treatment.
Empirical treatment for M. luteus infection has not 
yet reached any consensus. In the past, patients with 
native valve infective endocarditis and brain abscess 
due to M. luteus had been treated with vancomycin, 
aminoglycosides, rifampin, and beta-lactam antibiot-
ics, and all yielded good responses (Miltiadous and 
Elisaf 2011; Erbasan 2018; Ianniello et al. 2019; Khan 
et al. 2019). In FMC-PLAGH, cephalosporins and 
quinolones are frequently used empirically for they 
have a broad antibacterial spectrum and fewer adverse 
events. This strategy was also proven to be useful as 
most M. luteus strains were responsive to these anti-
biotics. For M. luteus strains that were less responsive 
to multiple antibiotics, vancomycin and teicoplanin 
are proper candidates as they showed good inhibiting 
ability against these strains (Table SI). Nevertheless, the 
frequent use of glycopeptides (26.7%) in this study was 
considered unnecessary and should be avoided, for it 
might give rise to the appearance of multidrug-resistant 
bacteria. Instead, for most M. luteus BSIs, cephalospor-
ins, quinolones, or other antibiotics other than macro-
lides will be enough for antimicrobial treatment.
However, this study has several limitations. The 
incidence of M. luteus BSI could vary among differ-
ent countries, regions, or even hospitals, giving rise 
to significant bias. Moreover, all the data in this study 
was collected retrospectively so that some details on 
patients’ symptoms could be lost. Therefore, further 
researches are still needed to discover more detailed 
features of M. luteus BSI.
Conclusions
As an unusual infection, M. luteus BSI mainly hap-
pens in immunocompromised patients or those with 
former invasive surgeries or indwelling catheters. 
High NEUT% and CRP levels were commonly seen 
in M. luteus BSI patients. M. luteus strains were mostly 
responsive to linezolid, cefoxitin, and rifampin, but 
were less responsive to erythromycin. Cephalosporins 
and quinolones are effective empirical antibiotics for 
M. luteus BSI; however, vancomycin and teicoplanin 
should be considered for potentially broadly drug-
resistant M. luteus strains.
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